Andreja Sinkovič1, Nejc Piko2, Matevž Privšek2, Andrej Markota2. 1. Department of Medical Intensive Care, University Clinical Centre Maribor, Ljubljanska 5, SI-2000, Maribor, Slovenia. andreja.sinkovic@guest.arnes.si. 2. Department of Medical Intensive Care, University Clinical Centre Maribor, Ljubljanska 5, SI-2000, Maribor, Slovenia.
Abstract
BACKGROUND: A decade ago women with ST-elevation myocardial infarction (STEMI) were significantly older than men, with more comorbidities, less likely treated by primary percutaneous coronary intervention (PPCI) and their prognosis was worse. The progress in treatment led to increased survival after STEMI. Our aim was to evaluate the possible current differences between the genders in treatments, mortality and the changes in women over time in STEMI population. METHODS: We retrospectively evaluated 307 STEMI patients (224 men, 83 women), admitted between October 1, 2011 and December 31, 2012 and a historic group of 523 STEMI patients from 2008 to 2009 (361 men, 162 women). Reperfusion strategy was PPCI, combined with aspirin and clopidogrel or prasugrel or ticagrelor and a heparin with glycoprotein receptor IIb/IIIa antagonist or bivalirudin. Between the genders and in women over time we compared clinical data, the use and time to PPCI, in-hospital complications, 30-day and 6-month mortality. RESULTS: STEMI patients in recent years were treated by PPCI in 94.5 %. Their 30-day mortality was 10.4 % and 6-month mortality 14.7 %. Between the genders we observed mostly nonsignificant differences (age, comorbidities, treatments, in-hospital complications, 30-day and 6-month mortality). Over the last years in women mean age significantly decreased, the use of PPCI significantly increased, the incidence of heart failure and bleedings decreased significantly, but mortalities nonsignificantly. CONCLUSION: Women still account for 1/4 of STEMI population, but the gap between the genders in presentation, treatments and outcome in STEMI population is decreasing.
BACKGROUND: A decade ago women with ST-elevation myocardial infarction (STEMI) were significantly older than men, with more comorbidities, less likely treated by primary percutaneous coronary intervention (PPCI) and their prognosis was worse. The progress in treatment led to increased survival after STEMI. Our aim was to evaluate the possible current differences between the genders in treatments, mortality and the changes in women over time in STEMI population. METHODS: We retrospectively evaluated 307 STEMI patients (224 men, 83 women), admitted between October 1, 2011 and December 31, 2012 and a historic group of 523 STEMI patients from 2008 to 2009 (361 men, 162 women). Reperfusion strategy was PPCI, combined with aspirin and clopidogrel or prasugrel or ticagrelor and a heparin with glycoprotein receptor IIb/IIIa antagonist or bivalirudin. Between the genders and in women over time we compared clinical data, the use and time to PPCI, in-hospital complications, 30-day and 6-month mortality. RESULTS: STEMI patients in recent years were treated by PPCI in 94.5 %. Their 30-day mortality was 10.4 % and 6-month mortality 14.7 %. Between the genders we observed mostly nonsignificant differences (age, comorbidities, treatments, in-hospital complications, 30-day and 6-month mortality). Over the last years in women mean age significantly decreased, the use of PPCI significantly increased, the incidence of heart failure and bleedings decreased significantly, but mortalities nonsignificantly. CONCLUSION:Women still account for 1/4 of STEMI population, but the gap between the genders in presentation, treatments and outcome in STEMI population is decreasing.
Entities:
Keywords:
Acute ST-elevation myocardial infarction; Men; Mortality; Treatment; Women
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Amber M Otten; Angela H E M Maas; Jan Paul Ottervanger; Anita Kloosterman; Arnoud W J van 't Hof; Jan Henk E Dambrink; A T Marcel Gosselink; Jan C A Hoorntje; Harry Suryapranata; Menko Jan de Boer Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-01-31
Authors: Matthijs A Velders; Helèn Boden; Adrianus J van Boven; Bas L van der Hoeven; Anton A C M Heestermans; Suzanne C Cannegieter; Victor A W M Umans; J Wouter Jukema; Sjoerd H Hofma; Martin J Schalij Journal: Am J Cardiol Date: 2012-11-15 Impact factor: 2.778
Authors: Sripal Bangalore; Gregg C Fonarow; Eric D Peterson; Anne S Hellkamp; Adrian F Hernandez; Warren Laskey; W Frank Peacock; Christopher P Cannon; Lee H Schwamm; Deepak L Bhatt Journal: Am J Med Date: 2012-06-27 Impact factor: 4.965
Authors: Dragana Radovanovic; Bramajee K Nallamothu; Burkhardt Seifert; Osmund Bertel; Franz Eberli; Philip Urban; Giovanni Pedrazzini; Hans Rickli; Jean-Christophe Stauffer; Stephan Windecker; Paul Erne Journal: Eur Heart J Acute Cardiovasc Care Date: 2012-09
Authors: Petr Widimsky; William Wijns; Jean Fajadet; Mark de Belder; Jiri Knot; Lars Aaberge; George Andrikopoulos; Jose Antonio Baz; Amadeo Betriu; Marc Claeys; Nicholas Danchin; Slaveyko Djambazov; Paul Erne; Juha Hartikainen; Kurt Huber; Petr Kala; Milka Klinceva; Steen Dalby Kristensen; Peter Ludman; Josephina Mauri Ferre; Bela Merkely; Davor Milicic; Joao Morais; Marko Noc; Grzegorz Opolski; Miodrag Ostojic; Dragana Radovanovic; Stefano De Servi; Ulf Stenestrand; Martin Studencan; Marco Tubaro; Zorana Vasiljevic; Franz Weidinger; Adam Witkowski; Uwe Zeymer Journal: Eur Heart J Date: 2009-11-19 Impact factor: 29.983